Lithium is not FDA-approved for treating acute bipolar depression. The FDA has approved lithium for two specific uses: treating manic episodes in bipolar disorder and long-term maintenance therapy to prevent future episodes. This means that when doctors prescribe lithium to treat a depressive episode in bipolar disorder, they are using it off-label.
What Lithium Is Actually Approved For
The FDA-approved labeling for lithium carbonate lists two indications. The first is treating active manic episodes, where it can normalize symptoms within one to three weeks. The second is maintenance treatment for people with a bipolar disorder diagnosis, meaning it’s approved to help prevent future mood episodes over time. Neither indication specifically covers acute depressive episodes.
This distinction matters because bipolar disorder involves two poles of mood disruption, and the FDA evaluated lithium’s effectiveness primarily against mania and recurrence. The agency never granted a separate approval for the depressive side of the illness, even though lithium has been used in clinical practice for decades.
How Well Lithium Works for Bipolar Depression
The evidence for lithium in acute bipolar depression is surprisingly modest. A systematic review and meta-analysis found no statistically significant difference between lithium and placebo for treating depressive episodes, though lithium did perform numerically better. It also performed numerically worse than antidepressants, though again the difference fell short of statistical significance. In practical terms, the data suggest lithium has some antidepressant effect in bipolar disorder, but it’s not strong enough to stand on its own as a frontline treatment for acute depression.
This is why most clinical guidelines, including the widely referenced CANMAT/ISBD guidelines, tend to recommend other medications as first-line options for acute bipolar depression. Lithium monotherapy is generally not the go-to choice when someone is in a depressive episode. Other mood stabilizers and certain antipsychotics have stronger evidence for pulling someone out of a bipolar depressive episode.
Where Lithium Shines: Prevention and Suicide Risk
Lithium’s real strength lies in preventing future episodes of both mania and depression over the long term. It is sometimes described as the gold standard for bipolar maintenance precisely because it is the only medication shown to be effective in preventing manic episodes, depressive episodes, and suicidal behavior. No other single drug covers all three.
The suicide prevention data is particularly notable. Meta-analyses have consistently found that people taking lithium have lower rates of suicide attempts and deaths compared to those on other treatments or placebo. The U.S. Department of Veterans Affairs clinical practice guidelines specifically suggest lithium to decrease suicide risk in patients with mood disorders. For many clinicians, this unique protective effect is a major reason to keep lithium in a patient’s treatment plan even when other medications are handling acute symptoms.
Blood Levels and Monitoring
Lithium has a narrow therapeutic window, meaning the difference between an effective dose and a harmful one is relatively small. For maintenance treatment, an international task force recommends a target blood level of 0.60 to 0.80 mmol/L. If you’re responding well but experiencing side effects, your doctor may lower the target to 0.40 to 0.60 mmol/L. If your response is insufficient and you’re tolerating it well, levels can be pushed up to 0.80 to 1.00 mmol/L. Blood levels below 0.40 mmol/L appear ineffective, so there’s no clinical rationale for staying that low.
Regular blood work is essential while taking lithium. Clinical guidelines recommend monitoring thyroid function and kidney health at baseline and periodically throughout treatment. Lithium can cause an underactive thyroid and, over time, can affect kidney filtration. Research has found that a considerable proportion of people on lithium don’t actually receive the recommended lab monitoring, which is a concern because early detection of these changes makes them far more manageable. If you’re on lithium, routine blood draws for kidney and thyroid markers are not optional.
Why Doctors Still Prescribe It for Depression
Even without an FDA indication for bipolar depression, lithium remains a common part of treatment plans for people experiencing depressive episodes. The reasoning is practical: many patients are already taking lithium for maintenance, and its ability to prevent depressive recurrences means it’s doing ongoing work even if it’s not the primary tool for treating an acute episode. Doctors frequently combine lithium with other medications that have stronger acute antidepressant effects in bipolar disorder.
Off-label prescribing is extremely common in psychiatry and doesn’t mean a medication is unproven or unsafe. It simply means the manufacturer never sought or obtained FDA approval for that specific use. In lithium’s case, the drug has been in clinical use since the 1960s, long before modern FDA approval processes required the kind of large, expensive trials that would support a depression-specific indication. The gap between its FDA label and its clinical use reflects the economics of drug approval more than the state of the science.